Bioequivalence of a new strength tacrolimus capsule under development.
Bekersky
I
I
Department of Experimental Therapeutics, Fujisawa USA, Inc, Deerfield 60015, USA.
Dressler
D
D
Boswell
G W
GW
Fergen
B
B
Tracewell
W
W
Mekki
Q
Q
D000284:Administration, Oral; D000328:Adult; D002214:Capsules; D003198:Computer Simulation; D016001:Confidence Intervals; D018592:Cross-Over Studies; D005006:Ethnicity; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D008657:Metabolic Clearance Rate; D044469:Racial Groups; D011897:Random Allocation; D016559:Tacrolimus / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency
D002214:Capsules; D007166:Immunosuppressive Agents; D016559:Tacrolimus